Suzanne Louise Bruhn

CIK: 0001517790

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)7 (87.5%)

Compensation grants

Other (G, F, J, C, D, …)1 (12.5%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (4)

DFTX

Definium Therapeutics, Inc.

Director

TVTX

Travere Therapeutics, Inc.

Director

VIGL

Vigil Neuroscience, Inc.

Director

PLRX

PLIANT THERAPEUTICS, INC.

Director

Discretionary Trading P&L

Holdings

Transaction History (8 total)

DFTX
Definium Therapeutics, Inc.
Jun 11, 2026
Award(A)
Direct
4.7K shares-
TVTX
Travere Therapeutics, Inc.
May 19, 2026
Award(A)
Direct
4K shares-
VIGL
Vigil Neuroscience, Inc.
Aug 5, 2025
Disposition(D)
Direct
5K shares-
MNMD
Mind Medicine (MindMed) Inc.
Jun 12, 2025
Award(A)
Stock Option (Right to Buy)
Direct
75.2K shares-
PLRX
PLIANT THERAPEUTICS, INC.
Jun 5, 2025
Award(A)
Common Stock (Right to Buy)
Direct
30K shares-
VIGL
Vigil Neuroscience, Inc.
May 22, 2025
Award(A)
Direct
5K shares-
TVTX
Travere Therapeutics, Inc.
May 15, 2025
Award(A)
Direct
6.5K shares-
VIGL
Vigil Neuroscience, Inc.
Mar 3, 2025
Award(A)
Stock Option Award (Right to Buy)
Direct
33.9K shares-

		Type	Shares	Price		Ownership
Jun 11, 2026	DFTX Definium Therapeutics, Inc.	Award(A)	4,666	-	$0	Direct
May 19, 2026	TVTX Travere Therapeutics, Inc.	Award(A)	4,000	-	$0	Direct
Aug 5, 2025	VIGL Vigil Neuroscience, Inc.	Disposition(D)	5,000	-	-	Direct
Jun 12, 2025	MNMD Mind Medicine (MindMed) Inc.	Award(A) Stock Option (Right to Buy)	75,187	-	-	Direct
Jun 5, 2025	PLRX PLIANT THERAPEUTICS, INC.	Award(A) Common Stock (Right to Buy)	30,000	-	-	Direct
May 22, 2025	VIGL Vigil Neuroscience, Inc.	Award(A)	5,000	-	-	Direct
May 15, 2025	TVTX Travere Therapeutics, Inc.	Award(A)	6,500	-	-	Direct
Mar 3, 2025	VIGL Vigil Neuroscience, Inc.	Award(A) Stock Option Award (Right to Buy)	33,875	-	-	Direct

1-8 of 8 transactions

About Bruhn Suzanne Louise

Bruhn Suzanne Louise (SEC CIK 0001517790) files insider reports with the SEC as Director of Definium Therapeutics, Inc. (DFTX), Director of Travere Therapeutics, Inc. (TVTX) and Director of Vigil Neuroscience, Inc. (VIGL). Signal8 also holds filings tied to 1 other company.

Signal8 holds 8 ownership filings by Bruhn Suzanne Louise, all Form 4s, filed between Mar 4, 2025 and Jun 15, 2026. Those filings report 8 transactions, from Mar 3, 2025 to Jun 11, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Bruhn Suzanne Louise's filings is in NEW YORK, NY.

Recent filings by Bruhn Suzanne Louise

Jun 11, 2026: Grant or award of DFTX shares (Form 4, code A).
May 19, 2026: Grant or award of TVTX shares (Form 4, code A).
Aug 5, 2025: Disposition to issuer transaction of VIGL shares (Form 4, code D).
Jun 12, 2025: Grant or award of MNMD derivative securities (Form 4, code A).
Jun 5, 2025: Grant or award of PLRX derivative securities (Form 4, code A).

Other insiders filing for Definium Therapeutics, Inc. (DFTX)

Karlin Daniel, Chief Medical Officer
Barrow Robert, Chief Executive Officer
Wiley Matthew T., Chief Commercial Officer
Sullivan Mark, Chief Legal Officer
Roberts Brandi, Chief Financial Officer
Vallone Carol A, Director

How to read Form 4 transaction codes